Ocuphire Pharma Inc (OCUP) Quote

Whatever you want to say to me, you can say publicly.. I didn't block anyone specifically.

OCUP under $2

OCUP under $2

Why you gotta be such a coward and block my personal message ???????

LoL LoL, you scared ????

IB_🤴🏻

OCUP....................................https://stockcharts.com/h-sc/ui?s=OCUP&p=W&b=5&g=0&id=p86431144783

OCUP under $2

Today looks like another new 52 week low... Comments or insights welcome.

Monksdream: do you like OCUP's fundamentals and stats?

OCUP new 52 lo

OCUP under $2

Hi, is this board alive?

How do longs allow something like this to happen? Fight back!!!

what a long slow journey $3.44 yuck

now finally back above my cost base..$5.89..weeeeee

skip

OCUP Company Overview

*Two Lead Assets for Front & Back of Eye - Eye Drop/Oral tablet
*$20 billion combined U.S. Market Opportunity - 4 advanced clinical trial indications
*$17MM cash(6/30); ZERO DEBT; Runway for 1 year ++
*Significant Near-Term catalysts
*Nyxol - Reversal of Dilation - NDA submission expected THIS QUARTER
*APX3330 - Diabetic Disease - Topline Phase2b data expected THIS QUARTER
*Ongoing Partnering Discussions with large ophthalmic Companies - world-wide
*Good analyst coverage

Trades: NASDAQ: OCUP
Market Cap: $45 million
52 Week H-L: $5.50 - 1.78
Current Price: $ 2.25

Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders.

The Company’s lead product candidate, Nyxol ® eye drops (0.75% phentolamine ophthalmic solution), is a once-daily, preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including reversal of pharmacologically-induced mydriasis (RM), presbyopia and dim light or night vision disturbances (NVD). Nyxol has been studied in 12 completed clinical trials, with positive data reported from the MIRA-2 and MIRA-3 registration trials and the MIRA-4 pediatric safety trial for the treatment of RM. Ocuphire also reported positive top-line data from the VEGA-1 Phase 2 trial of Nyxol for treatment of presbyopia, which evaluated both Nyxol as a single agent and Nyxol with low dose pilocarpine (“LDP”) 0.4% as adjunctive therapy. The Company recently announced positive top-line results from the LYNX-1 Phase 3 trial of Nyxol for night vision disturbances (NVD).

Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). APX3330 has been studied in 11 Phase 1 and 2 trials and currently completed enrollment and treatment of 103 DR patients in multi-center, randomized, double-masked, placebo-controlled, 24-week ZETA-1 Phase 2b trial.

If it wasn't for the election stuff, this would probably have gone to $3s today.

Analysts calling for 24-26$ target

This may just rise all day with that upfront payment and the one following up to that in the future... Governments are misappropriating funds to Pharma.... That is where you can take advantage

Nice news but seems someone is shorting everything.

Not the best day to put out news. (US elections)

Still waiting for this to favorably turn

I guess today's news wasn't good enough :(

Yes I'm waiting even if it takes another year. But this REALLY hurts

At this point, seems best to wait for a few catalyst events (Jan 31 Investor Meeting, results from phase 3 studies in Q1, etc). In the meantime, I question that decision every day this PPS drops.

amen

My heart is breaking on this one :'(

These red days are getting rather annoying

And the bleeding continues :(

What the flying f**k!

Took some call options today looking good for swing next week

Too late to run....I'm a long term holder now

Aholes are making $ by letting shorts short it now... RUN!! Screen recorded every transaction. Will report. ALWAYS HELPS TO HAVE A FAM MEMBER THAT WORKS AT THE SEC!! :)

I'm an official bagholder

I can literally see the CEO and cohorts being thankful for their profits off of retail. I will bash this stock forever and from now on. CROOKS!!!

DILUTION POS's selling into good news.. SO sad! Guess they need the $$ on the backs of retail... Happy Thanksgiving OCUP insiders. Retail dose not forget the BS!

So finding some shares to short might be a better trading strategy. Usually is after the big runs

Anytime Wainwright upgrades a micro pharma with a ridiculous price target it is a signal of insider selling

100X daily volume premarket. PPS NOT to the moon. News = sale stock?

OCUP

OCUP > Thanksgiving turkey trot > shorts to become cranberry sauce!

15M volume in premarket! > super low float runner >

Hit $13 with early March news. Should fly again

Occupied with OCUP.....

PT > 26.00 > HC Wainwright & Co. analyst Andrew Fein initiates coverage on Ocuphire Pharma (NASDAQ:OCUP) with a Buy rating and announces Price Target of $26.

OCUP

This will go up 500-800% minimum from here.

i shorted 6.40 earlier. covered way too soon 6.12.

5.57 now

This looked really nice at the start of pre-market. I'll have to wait and see what happens at open.

Good luck today.

6.12 shorts pounding it but already traded the entire OS

https://finviz.com/quote.ashx?t=ocup

added 6.28 on this PB previous run to $20 March 15-21 https://finviz.com/quote.ashx?t=ocup

$8.50 down to $6.40 -- Pre-market trading looks like a pump and dump.

OCUP Split History Table
Date Ratio
11/06/2020 1 for 4

Traded pre-market over $8.50 down to $6.50 on massive dump.